Resverlogix (RVX) Stock Price, News & Analysis

Company Overview

Resverlogix Corp., a late-stage clinical biotechnology company, develops therapeutics for disease states with high unmet medical needs. Its lead drug is apabetalone (RVX-208), a small molecule selective bromodomain and extra-terminal inhibitor that is in Phase III clinical trial for patients with cardiovascular disease, diabetes mellitus, chronic kidney disease, end-stage renal disease, and neurodegenerative diseases. Resverlogix Corp. has a partnership with Eversana Life Science Services, LLC to support the pending launch of the commercialization of apabetalone for Covid-19 in the United States and Canada; and developing cardiovascular and pulmonary arterial hypertension indications. The company was founded in 2001 and is headquartered in Calgary, Canada.

Key Stats

• Today's Range: C$0.06 to C$0.06
• 50-Day Range: C$0.05 to C$0.07
• 52-Week Range: C$0.04 to C$0.10
• Volume: 173,200 shs
• Average Volume: 60,153 shs
• Market Capitalization: C$16.62 million
• P/E Ratio: N/A
• Dividend Yield: 7.02%
• Price Target: N/A
• Consensus Rating: N/A

RVX Stock Analysis - Frequently Asked Questions

How have RVX shares performed this year?

Resverlogix's stock was trading at C$0.07 on January 1st, 2024. Since then, RVX shares have decreased by 14.3% and is now trading at C$0.06.
View the best growth stocks for 2024 here.

How do I buy shares of Resverlogix?

Shares of RVX stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

What other stocks do shareholders of Resverlogix own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Resverlogix investors own include ProMetic Life Sciences (PLI), Aptose Biosciences (APTO), Antibe Therapeutics (ATE), Oncolytics Biotech (ONC), Radient Technologies (RTI), VentriPoint Diagnostics (VPT) and Burcon NutraScience (BU).

Company Calendar

• Today: 11/20/2024
• Next Earnings (Estimated): 4/07/2025

Industry, Sector and Symbol

• Stock Exchange: TSE
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: TSE:RVX
• CUSIP: N/A
• CIK: N/A
• Web: www.resverlogix.com
• Phone: +1-403-2549252
• Fax: N/A
• Employees: 19
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): C($0.05)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: C$-10,740,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: -34.90%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.07
• Quick Ratio: 0.04

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: C$0.00 per share
• Price / Cash Flow: 132.50
• Book Value: C($0.28) per share
• Price / Book: -0.20

Miscellaneous

• Outstanding Shares: 276,970,000
• Free Float: N/A
• Market Cap: C$15.23 million
• Optionable: Not Optionable
• Beta: 0.71